Demethylation	O
of	O
the	O
Coding	O
Region	O
Triggers	O
the	O
Activation	O
of	O
the	O
Human	B-OG
Testis	O
-	O
Specific	O
PDHA2	B-GP
Gene	O
in	O
Somatic	O
Tissues	O

Conceived	O
and	O
designed	O
the	O
experiments	O
:	O
IR	O
ER	O
.	O

Performed	O
the	O
experiments	O
:	O
AP	O
MJN	O
IM	O
MJS	O
.	O

Analyzed	O
the	O
data	O
:	O
IR	O
ER	O
ITA	O
.	O

Contributed	O
reagents	O
/	O
materials	O
/	O
analysis	O
tools	O
:	O
MJS	O
ITA	O
.	O

Wrote	O
the	O
paper	O
:	O
IR	O
ER	O
AP	O
.	O

Human	B-OG
PDHA2	B-GP
is	O
a	O
testis	O
-	O
specific	O
gene	O
that	O
codes	O
for	O
the	O
E1α	B-GP
subunit	I-GP
of	O
Pyruvate	B-GP
Dehydrogenase	I-GP
Complex	I-GP
(	O
PDC	B-GP
),	O
a	O
crucial	O
enzyme	O
system	O
in	O
cell	O
energy	O
metabolism	O
.	O

Since	O
activation	O
of	O
the	O
PDHA2	B-GP
gene	O
in	O
somatic	O
cells	O
could	O
be	O
a	O
new	O
therapeutic	O
approach	O
for	O
PDC	B-DS
deficiency	I-DS
,	O
we	O
aimed	O
to	O
identify	O
the	O
regulatory	O
mechanisms	O
underlying	O
the	O
human	B-OG
PDHA2	B-GP
gene	O
expression	O
.	O

Functional	O
deletion	O
studies	O
revealed	O
that	O
the	O
−	O
122	O
to	O
−	O
6	O
promoter	O
region	O
is	O
indispensable	O
for	O
basal	O
expression	O
of	O
this	O
TATA	O
-	O
less	O
promoter	O
,	O
and	O
suggested	O
a	O
role	O
of	O
an	O
epigenetic	O
program	O
in	O
the	O
control	O
of	O
PDHA2	B-GP
gene	O
expression	O
.	O

Indeed	O
,	O
treatment	O
of	O
SH	O
-	O
SY5Y	O
cells	O
with	O
the	O
hypomethylating	O
agent	O
5	O
-	O
Aza	O
-	O
2	O
′-	O
deoxycytidine	O
(	O
DAC	O
)	O
promoted	O
the	O
reactivation	O
of	O
the	O
PDHA2	B-GP
gene	O
,	O
by	O
inducing	O
the	O
recruitment	O
of	O
the	O
RNA	B-GP
polymerase	I-GP
II	I-GP
to	O
the	O
proximal	O
promoter	O
region	O
and	O
the	O
consequent	O
increase	O
in	O
PDHA2	B-GP
mRNA	O
levels	O
.	O

Bisulfite	O
sequencing	O
analysis	O
revealed	O
that	O
DAC	O
treatment	O
induced	O
a	O
significant	O
demethylation	O
of	O
the	O
CpG	O
island	O
II	O
(	O
nucleotides	O
+	O
197	O
to	O
+	O
460	O
)	O
in	O
PDHA2	B-GP
coding	O
region	O
,	O
while	O
the	O
promoter	O
region	O
remained	O
highly	O
methylated	O
.	O

Taken	O
together	O
with	O
our	O
previous	O
results	O
that	O
show	O
an	O
in	O
vivo	O
correlation	O
between	O
PDHA2	B-GP
expression	O
and	O
the	O
demethylation	O
of	O
the	O
CpG	O
island	O
II	O
in	O
testis	O
germ	O
cells	O
,	O
the	O
present	O
results	O
show	O
that	O
internal	O
methylation	O
of	O
the	O
PDHA2	B-GP
gene	O
plays	O
a	O
part	O
in	O
its	O
repression	O
in	O
somatic	O
cells	O
.	O

In	O
conclusion	O
,	O
our	O
data	O
support	O
the	O
novel	O
finding	O
that	O
methylation	O
of	O
the	O
PDHA2	B-GP
coding	O
region	O
can	O
inhibit	O
gene	O
transcription	O
.	O

This	O
represents	O
a	O
key	O
mechanism	O
for	O
absence	O
of	O
PDHA2	B-GP
expression	O
in	O
somatic	O
cells	O
and	O
a	O
target	O
for	O
PDC	B-GP
therapy	O
.	O

Introduction	O

Pyruvate	B-GP
dehydrogenase	I-GP
complex	I-GP
(	O
PDC	B-GP
)	O
is	O
a	O
mitochondrial	O
matrix	O
enzyme	O
system	O
that	O
catalyses	O
the	O
oxidative	O
decarboxylation	O
of	O
pyruvate	O
to	O
acetyl	O
-	O
CoA	O
,	O
a	O
key	O
metabolite	O
for	O
energy	O
metabolism	O
.	O

The	O
rate	O
-	O
limiting	O
component	O
is	O
the	O
E1	B-GP
enzyme	I-GP
,	O
which	O
is	O
a	O
heterotetramer	O
(	O
α2β2	O
).	O

The	O
α	O
subunit	O
,	O
besides	O
forming	O
with	O
the	O
β	O
subunit	O
the	O
active	O
and	O
the	O
cofactor	O
binding	O
sites	O
,	O
is	O
also	O
the	O
target	O
for	O
regulatory	O
mechanisms	O
governing	O
global	O
activity	O
of	O
PDC	B-GP
.	O

The	O
E1α	B-GP
subunit	I-GP
can	O
be	O
encoded	O
by	O
two	O
different	O
genes	O
:	O
PDHA1	B-GP
located	O
on	O
X	O
chromosome	O
and	O
expressed	O
in	O
somatic	O
tissues	O
;	O
and	O
PDHA2	B-GP
an	O
intronless	O
gene	O
located	O
on	O
chromosome	O
4	O
(	O
Fig	O
.	O
1	O
).	O

This	O
autosomal	O
gene	O
is	O
repressed	O
in	O
all	O
somatic	O
tissues	O
but	O
actively	O
transcribed	O
in	O
post	O
-	O
meiotic	O
germ	O
cells	O
where	O
the	O
X	O
chromosome	O
is	O
absent	O
or	O
inactive	O
[	O
1	O
],	O
[	O
2	O
].	O

It	O
was	O
suggested	O
that	O
the	O
translocation	O
of	O
PDHA	B-GP
to	O
the	O
eutherian	O
X	O
chromosome	O
,	O
which	O
is	O
inactivated	O
during	O
spermatogenesis	O
,	O
led	O
to	O
the	O
evolution	O
of	O
this	O
second	O
testis	O
-	O
specific	O
locus	O
by	O
retroposition	O
to	O
an	O
autosome	O
[	O
3	O
].	O

Schematic	O
representation	O
of	O
the	O
PDHA2	B-GP
gene	O
showing	O
the	O
localization	O
of	O
the	O
2	O
CpG	O
islands	O
(	O
CpG	O
I	O
and	O
CpG	O
II	O
),	O
the	O
transcriptional	O
start	O
site	O
and	O
the	O
putative	O
Sp1	B-GP
binding	O
site	O
.	O

Besides	O
the	O
potential	O
of	O
PDHA2	B-GP
as	O
a	O
model	O
for	O
unraveling	O
the	O
mechanisms	O
that	O
govern	O
gene	O
expression	O
during	O
spermatogenesis	O
[	O
4	O
],	O
some	O
authors	O
also	O
postulated	O
that	O
PDHA2	B-GP
gene	O
activation	O
in	O
somatic	O
cells	O
could	O
be	O
an	O
effective	O
therapy	O
for	O
PDC	B-DS
deficiency	I-DS
[	O
5	O
],	O
an	O
inborn	O
error	O
of	O
metabolism	O
mainly	O
caused	O
by	O
mutations	O
in	O
PDHA1	B-GP
gene	O
[	O
6	O
].	O

The	O
amount	O
of	O
published	O
work	O
on	O
PDHA2	B-GP
gene	O
regulation	O
is	O
scarce	O
and	O
the	O
studies	O
performed	O
relied	O
on	O
the	O
mouse	B-OG
orthologue	O
,	O
Pdha2	B-GP
[	O
4	O
],	O
[	O
7	O
],	O
[	O
8	O
],	O
[	O
9	O
],	O
[	O
10	O
].	O

However	O
,	O
it	O
is	O
believed	O
that	O
the	O
regulatory	O
mechanisms	O
that	O
control	O
these	O
orthologous	O
genes	O
are	O
different	O
,	O
once	O
there	O
is	O
no	O
gross	O
homology	O
between	O
their	O
promoters	O
,	O
which	O
seem	O
to	O
have	O
evolved	O
from	O
different	O
retroposons	O
[	O
11	O
].	O

Datta	O
and	O
collaborators	O
publish	O
the	O
first	O
and	O
,	O
to	O
our	O
knowledge	O
,	O
unique	O
study	O
on	O
human	B-OG
PDHA2	B-GP
gene	O
regulation	O
[	O
5	O
].	O

They	O
isolated	O
and	O
characterized	O
approximately	O
800	O
nucleotides	O
of	O
the	O
PDHA2	B-GP
promoter	O
region	O
,	O
identified	O
the	O
location	O
of	O
the	O
transcription	O
start	O
site	O
and	O
performed	O
functional	O
studies	O
that	O
suggested	O
the	O
existence	O
of	O
multiple	O
regulatory	O
elements	O
.	O

More	O
importantly	O
,	O
these	O
authors	O
proposed	O
that	O
the	O
PDHA2	B-GP
tissue	O
-	O
specific	O
expression	O
could	O
be	O
modulated	O
by	O
mechanisms	O
,	O
such	O
as	O
DNA	O
methylation	O
,	O
that	O
would	O
limit	O
PDHA2	B-GP
expression	O
to	O
spermatogenic	O
cells	O
.	O

Indeed	O
,	O
DNA	O
methylation	O
is	O
a	O
widely	O
known	O
epigenetic	O
mechanism	O
that	O
plays	O
a	O
central	O
role	O
in	O
the	O
selective	O
expression	O
of	O
particular	O
genes	O
in	O
different	O
tissues	O
.	O

The	O
methylation	O
of	O
cytosine	O
residues	O
acts	O
as	O
a	O
negative	B-GP
regulator	I-GP
of	I-GP
transcription	I-GP
by	O
three	O
potential	O
mechanisms	O
:	O
direct	O
interference	O
with	O
the	O
binding	O
of	O
specific	O
transcription	B-GP
factors	I-GP
to	O
promoters	O
,	O
direct	O
binding	O
of	O
specific	O
transcriptional	B-GP
repressors	I-GP
and	O
alteration	O
of	O
the	O
chromatin	O
structure	O
[	O
12	O
].	O

DNA	O
methylation	O
can	O
be	O
inhibited	O
by	O
5	O
-	O
Aza	O
-	O
2	O
′-	O
deoxycytidine	O
(	O
DAC	O
),	O
a	O
potent	O
inhibitor	O
of	O
DNA	B-GP
methyltransferase	I-GP
(	O
DNMT	B-GP
)	O
activity	O
,	O
through	O
the	O
irreversible	O
binding	O
of	O
DNMTs	B-GP
to	O
DAC	O
substituted	O
DNA	O
[	O
13	O
].	O

Recently	O
,	O
we	O
have	O
demonstrated	O
an	O
in	O
vivo	O
correlation	O
between	O
an	O
increase	O
in	O
PDHA2	B-GP
mRNA	O
levels	O
and	O
the	O
demethylation	O
of	O
a	O
CpG	O
island	O
in	O
its	O
coding	O
region	O
[	O
14	O
],	O
which	O
is	O
a	O
strong	O
evidence	O
for	O
a	O
role	O
of	O
DNA	O
methylation	O
in	O
the	O
epigenetic	O
control	O
of	O
the	O
human	B-OG
PDHA2	B-GP
gene	O
.	O

In	O
this	O
study	O
we	O
show	O
that	O
inhibition	O
of	O
DNMTs	B-GP
with	O
DAC	O
reactivates	O
PDHA2	B-GP
gene	O
expression	O
in	O
SH	O
-	O
SY5Y	O
cells	O
,	O
in	O
a	O
demethylation	O
-	O
dependent	O
manner	O
.	O

Results	O

PDHA2	B-GP
promoter	O
constructs	O
display	O
basal	O
activity	O
in	O
human	B-OG
somatic	O
cell	O
lines	O

Human	B-OG
PDHA2	B-GP
gene	O
expression	O
is	O
restricted	O
to	O
post	O
-	O
meiotic	O
germ	O
cells	O
[	O
2	O
]	O
suggesting	O
the	O
absence	O
of	O
positive	O
modulating	O
factors	O
and	O
/	O
or	O
the	O
presence	O
of	O
repressors	O
in	O
somatic	O
tissues	O
.	O

However	O
,	O
the	O
lack	O
of	O
suitable	O
human	B-OG
spermatogenic	O
germ	O
cell	O
lines	O
makes	O
it	O
difficult	O
to	O
easily	O
elucidate	O
the	O
regulatory	O
mechanisms	O
involved	O
upon	O
PDHA2	B-GP
expression	O
.	O

In	O
order	O
to	O
evaluate	O
the	O
regions	O
important	O
for	O
transcriptional	O
modulation	O
and	O
,	O
more	O
precisely	O
,	O
to	O
define	O
the	O
regions	O
putatively	O
involved	O
in	O
the	O
repression	O
of	O
PDHA2	B-GP
gene	O
in	O
somatic	O
cells	O
,	O
several	O
deletion	O
promoter	O
constructs	O
were	O
generated	O
(	O
Fig	O
.	O
2	O
),	O
and	O
their	O
ability	O
to	O
direct	O
expression	O
of	O
the	O
reporter	O
luciferase	B-GP
gene	O
was	O
analyzed	O
after	O
transient	O
transfection	O
in	O
different	O
somatic	O
cell	O
lines	O
.	O

Accordingly	O
,	O
the	O
various	O
PDHA2	B-GP
reporter	O
plasmids	O
and	O
the	O
parental	O
pGL2	O
-	O
Basic	O
vector	O
were	O
transfected	O
into	O
HeLa	O
(	O
cervix	B-DS
adenocarcinoma	I-DS
),	O
NT2	O
(	O
human	B-OG
teratocarcinoma	B-DS
)	O
and	O
SH	O
-	O
SY5Y	O
(	O
human	B-OG
neuroblastoma	B-DS
)	O
cells	O
,	O
which	O
do	O
not	O
normally	O
express	O
PDHA2	B-GP
mRNA	O
.	O

Functional	O
deletion	O
analysis	O
of	O
the	O
human	B-OG
PDHA2	B-GP
gene	O
promoter	O
.	O

Progressive	O
5	O
′	O
deletion	O
constructs	O
were	O
transiently	O
transfected	O
into	O
HeLa	O
,	O
NT2	O
and	O
SH	O
-	O
SY5Y	O
cell	O
lines	O
.	O

Transfections	O
were	O
carried	O
out	O
using	O
0	O
.	O
5	O
µg	O
of	O
the	O
PDHA2	B-GP
reporter	O
constructs	O
or	O
the	O
empty	O
pGL2	O
vector	O
.	O

Normalized	O
luciferase	B-GP
activities	O
were	O
expressed	O
as	O
mean	O
values	O
±	O
SEM	O
of	O
duplicates	O
for	O
a	O
minimum	O
of	O
three	O
experiments	O
(*	O
p	O
<	O
0	O
.	O
001	O
).	O

Surprisingly	O
,	O
PDHA2	B-GP
reporter	O
constructs	O
displayed	O
high	O
luciferase	B-GP
activities	O
in	O
all	O
three	O
somatic	O
cell	O
lines	O
(	O
Fig	O
.	O
2	O
).	O

Significant	O
differences	O
were	O
found	O
between	O
the	O
luciferase	B-GP
activities	O
of	O
the	O
several	O
constructs	O
,	O
in	O
HeLa	O
(	O
ANOVA	O
one	O
-	O
way	O
test	O
:	O
F	O
=	O
20	O
.	O
29	O
,	O
df	O
=	O
10	O
,	O
p	O
<	O
0	O
.	O
001	O
),	O
NT2	O
(	O
ANOVA	O
one	O
-	O
way	O
test	O
:	O
F	O
=	O
26	O
.	O
01	O
,	O
df	O
=	O
10	O
,	O
p	O
<	O
0	O
.	O
001	O
),	O
and	O
SH	O
-	O
SY5Y	O
(	O
ANOVA	O
one	O
-	O
way	O
test	O
:	O
F	O
=	O
48	O
.	O
89	O
,	O
df	O
=	O
10	O
,	O
p	O
<	O
0	O
.	O
001	O
)	O
cells	O
.	O

However	O
,	O
post	O
hoc	O
comparisons	O
only	O
revealed	O
significant	O
differences	O
between	O
the	O
luciferase	B-GP
activities	O
of	O
the	O
empty	O
pGL2	O
-	O
Basic	O
and	O
all	O
the	O
other	O
reporter	O
constructs	O
(	O
Tukey	O
HSD	O
p	O
<	O
0	O
.	O
001	O
).	O

These	O
results	O
firstly	O
show	O
that	O
the	O
region	O
between	O
nucleotides	O
−	O
122	O
and	O
−	O
6	O
seems	O
to	O
contain	O
all	O
the	O
sequences	O
necessary	O
to	O
drive	O
transcription	O
initiation	O
,	O
and	O
thus	O
most	O
probably	O
corresponding	O
to	O
the	O
basal	O
proximal	O
promoter	O
.	O

Secondly	O
,	O
the	O
fact	O
that	O
PDHA2	B-GP
promoter	O
reporter	O
constructs	O
present	O
high	O
luciferase	B-GP
activity	O
in	O
somatic	O
cell	O
lines	O
where	O
the	O
PDHA2	B-GP
mRNA	O
cannot	O
be	O
detected	O
,	O
and	O
that	O
there	O
are	O
no	O
significant	O
differences	O
between	O
the	O
luciferase	B-GP
activities	O
of	O
the	O
different	O
deletion	O
constructs	O
,	O
suggest	O
an	O
important	O
role	O
of	O
epigenetic	O
modifications	O
in	O
the	O
regulation	O
PDHA2	B-GP
tissue	O
-	O
specific	O
expression	O
.	O

In	O
vitro	O
methylation	O
prevents	O
PDHA2	B-GP
promoter	O
constructs	O
activity	O

To	O
evaluate	O
the	O
role	O
of	O
DNA	O
methylation	O
on	O
the	O
activity	O
of	O
the	O
PDHA2	B-GP
proximal	O
promoter	O
,	O
we	O
performed	O
an	O
in	O
vitro	O
methylation	O
assay	O
using	O
SssI	B-GP
methylase	I-GP
(	O
Fig	O
.	O
3A	O
).	O

The	O
results	O
revealed	O
that	O
the	O
PDHA2	B-GP
proximal	O
promoter	O
activity	O
was	O
completely	O
abolished	O
after	O
in	O
vitro	O
methylation	O
(	O
Fig	O
.	O
3B	O
).	O

Moreover	O
,	O
since	O
we	O
had	O
previously	O
demonstrated	O
an	O
in	O
vivo	O
inverted	O
correlation	O
between	O
methylation	O
of	O
a	O
CpG	O
island	O
localized	O
in	O
the	O
coding	O
region	O
(	O
see	O
CpG	O
II	O
in	O
Fig	O
.	O
1	O
)	O
and	O
the	O
PDHA2	B-GP
mRNA	O
levels	O
[	O
14	O
],	O
we	O
wanted	O
to	O
assess	O
if	O
the	O
presence	O
of	O
a	O
methylated	O
CpG	O
island	O
II	O
region	O
could	O
further	O
decrease	O
PDHA2	B-GP
construct	O
'	O
s	O
luciferase	B-GP
activity	O
.	O

Nevertheless	O
,	O
since	O
there	O
were	O
already	O
no	O
significant	O
differences	O
between	O
the	O
luciferase	B-GP
activity	O
of	O
the	O
296	O
.	O
pGL2	O
construct	O
and	O
of	O
the	O
empty	O
pGL2	O
.	O
Basic	O
vector	O
(	O
Fig	O
.	O
3B	O
and	O
3C	O
),	O
the	O
inclusion	O
of	O
the	O
CpG	O
II	O
region	O
did	O
not	O
result	O
in	O
a	O
further	O
decrease	O
in	O
promoter	O
activity	O
.	O

In	O
vitro	O
methylation	O
with	O
SssI	B-GP
methylase	I-GP
abrogates	O
PDHA2	B-GP
promoter	O
constructs	O
activity	O
.	O

Constructs	O
,	O
either	O
methylated	O
or	O
mock	O
-	O
methylated	O
,	O
were	O
transiently	O
transfected	O
into	O
SH	O
-	O
SY5Y	O
cell	O
line	O
.	O

Transfections	O
were	O
carried	O
out	O
using	O
0	O
.	O
5	O
µg	O
of	O
the	O
PDHA2	B-GP
reporter	O
constructs	O
or	O
the	O
empty	O
pGL2	O
vector	O
.	O

Normalized	O
luciferase	B-GP
activities	O
were	O
expressed	O
as	O
mean	O
values	O
±	O
SEM	O
of	O
duplicates	O
for	O
a	O
minimum	O
of	O
three	O
experiments	O
(*	O
p	O
<	O
0	O
.	O
001	O
).	O

(	O
A	O
)	O
Control	O
of	O
the	O
methylation	O
reaction	O
by	O
digestion	O
with	O
the	O
methylation	O
-	O
sensitive	O
endonuclease	B-GP
HpaII	I-GP
.	O

(	O
B	O
)	O
Methylation	O
of	O
PDHA2	B-GP
constructs	O
prevents	O
proximal	O
promoter	O
activity	O
.	O

(	O
C	O
)	O
No	O
significant	O
decrease	O
in	O
the	O
luciferase	B-GP
activity	O
was	O
observed	O
in	O
the	O
PDHA2	B-GP
construct	O
including	O
the	O
CpG	O
II	O
region	O
(	O
CpGs	O
.	O
pGL2	O
).	O

These	O
results	O
indeed	O
show	O
that	O
methylation	O
plays	O
an	O
important	O
repressive	O
role	O
upon	O
PDHA2	B-GP
gene	O
expression	O
.	O

Activation	O
of	O
PDHA2	B-GP
expression	O
in	O
somatic	O
cells	O
after	O
treatment	O
with	O
epigenetic	O
drugs	O

To	O
further	O
investigate	O
the	O
role	O
of	O
epigenetic	O
mechanisms	O
upon	O
PDHA2	B-GP
gene	O
regulation	O
,	O
we	O
treated	O
SH	O
-	O
SY5Y	O
cells	O
,	O
where	O
this	O
gene	O
is	O
not	O
normally	O
expressed	O
,	O
with	O
a	O
potent	O
inhibitor	O
of	O
the	O
de	O
novo	O
methylation	O
(	O
DAC	O
)	O
and	O
with	O
a	O
pharmacological	O
inhibitor	O
of	O
histone	B-GP
deacetylases	I-GP
(	O
TSA	O
).	O

PDHA2	B-GP
expression	O
was	O
quantified	O
by	O
real	O
-	O
time	O
PCR	O
(	O
qPCR	O
)	O
and	O
the	O
results	O
revealed	O
that	O
after	O
treatment	O
with	O
5	O
µM	O
DAC	O
for	O
96	O
h	O
or	O
120	O
h	O
,	O
there	O
is	O
a	O
significant	O
increase	O
of	O
PDHA2	B-GP
mRNA	O
,	O
when	O
compared	O
with	O
untreated	O
cells	O
(	O
ANOVA	O
one	O
-	O
way	O
test	O
:	O
F	O
=	O
27	O
.	O
84	O
,	O
df	O
=	O
3	O
,	O
p	O
<	O
0	O
.	O
001	O
;	O
Tukey	O
HSD	O
for	O
unequal	O
N	O
p	O
<	O
0	O
.	O
001	O
)	O
(	O
Fig	O
.	O
4A	O
).	O

DAC	O
increases	O
PDHA2	B-GP
mRNA	O
levels	O
in	O
SH	O
-	O
SY5Y	O
cells	O
.	O

Real	O
-	O
time	O
PCR	O
analysis	O
of	O
PDHA2	B-GP
steady	O
-	O
state	O
mRNA	O
transcript	O
levels	O
in	O
SH	O
-	O
SY5Y	O
cells	O
treated	O
with	O
5	O
µM	O
DAC	O
for	O
the	O
indicated	O
time	O
points	O
(	O
A	O
),	O
and	O
with	O
5	O
µM	O
DAC	O
for	O
96	O
h	O
and	O
/	O
or	O
0	O
.	O
25	O
µM	O
TSA	O
for	O
24	O
h	O
(	O
B	O
).	O

Values	O
were	O
normalized	O
to	O
the	O
internal	O
standard	O
β	B-GP
-	I-GP
actin	I-GP
.	O

Data	O
represent	O
means	O
±	O
SEM	O
of	O
at	O
least	O
three	O
independent	O
experiments	O
and	O
was	O
expressed	O
as	O
pg	O
of	O
PDHA2	B-GP
mRNA	O
per	O
ng	O
of	O
β	B-GP
-	I-GP
actin	I-GP
mRNA	O
(*	O
p	O
<	O
0	O
.	O
001	O
;	O
§	O
p	O
<	O
0	O
.	O
01	O
).	O

Since	O
it	O
is	O
generally	O
accepted	O
that	O
DAC	O
and	O
TSA	O
synergistically	O
affect	O
gene	O
expression	O
,	O
by	O
a	O
mechanism	O
that	O
depends	O
on	O
promoter	O
demethylation	O
induced	O
by	O
DAC	O
and	O
subsequent	O
reinforcement	O
by	O
histone	B-GP
acetylation	O
induced	O
by	O
TSA	O
,	O
we	O
also	O
treated	O
SH	O
-	O
SY5Y	O
with	O
TSA	O
for	O
24	O
h	O
,	O
and	O
with	O
DAC	O
for	O
96	O
h	O
prior	O
to	O
a	O
24	O
h	O
treatment	O
with	O
TSA	O
.	O

Incubation	O
with	O
0	O
.	O
25	O
µM	O
TSA	O
for	O
24	O
h	O
did	O
not	O
significantly	O
affect	O
PDHA2	B-GP
mRNA	O
levels	O
.	O

Moreover	O
,	O
pretreatment	O
with	O
DAC	O
for	O
96	O
h	O
,	O
prior	O
to	O
the	O
24	O
h	O
TSA	O
treatment	O
,	O
did	O
not	O
further	O
increase	O
the	O
observed	O
PDHA2	B-GP
mRNA	O
accumulation	O
with	O
DAC	O
treatment	O
only	O
(	O
Fig	O
.	O
4B	O
).	O

In	O
order	O
to	O
corroborate	O
the	O
fact	O
that	O
DAC	O
treatment	O
induces	O
a	O
derepression	O
of	O
PDHA2	B-GP
gene	O
transcription	O
,	O
we	O
analyzed	O
the	O
recruitment	O
of	O
RNA	B-GP
polymerase	I-GP
II	I-GP
(	O
RNA	B-GP
pol	I-GP
II	I-GP
)	O
to	O
this	O
gene	O
by	O
chromatin	O
immunoprecipitation	O
.	O

We	O
have	O
designed	O
three	O
sets	O
of	O
primers	O
,	O
one	O
targeting	O
the	O
promoter	O
region	O
(+	O
1	O
bp	O
),	O
another	O
targeting	O
a	O
distal	O
upstream	O
region	O
(−	O
10	O
kb	O
)	O
and	O
a	O
third	O
one	O
targeting	O
the	O
CpG	O
island	O
II	O
(+	O
385	O
pb	O
).	O

Our	O
results	O
showed	O
that	O
we	O
could	O
only	O
detect	O
RNA	B-GP
pol	I-GP
II	I-GP
binding	O
to	O
the	O
+	O
1	O
bp	O
region	O
after	O
DAC	O
treatment	O
(	O
Student	O
'	O
s	O
t	O
-	O
test	O
,	O
p	O
<	O
0	O
.	O
001	O
),	O
which	O
most	O
likely	O
triggers	O
the	O
observed	O
increase	O
in	O
PDHA2	B-GP
gene	O
transcription	O
(	O
Fig	O
.	O
5	O
).	O

Interestingly	O
,	O
we	O
could	O
not	O
detect	O
the	O
occupancy	O
of	O
the	O
putative	O
Sp	O
binding	O
site	O
,	O
by	O
the	O
Sp1	B-GP
transcription	B-GP
factor	I-GP
(	O
Fig	O
.	O
5	O
),	O
as	O
previously	O
suggested	O
by	O
Datta	O
and	O
co	O
-	O
workers	O
[	O
5	O
].	O

Furthermore	O
,	O
we	O
investigated	O
the	O
possible	O
recruitment	O
of	O
the	O
elongation	O
marker	O
H3K36me3	O
to	O
the	O
gene	O
body	O
,	O
but	O
the	O
results	O
showed	O
no	O
occupancy	O
of	O
the	O
targeted	O
region	O
.	O

Recruitment	O
of	O
RNA	B-GP
pol	I-GP
II	I-GP
to	O
the	O
human	B-OG
PDHA2	B-GP
gene	O
.	O

Chromatin	O
from	O
SH	O
-	O
SY5Y	O
was	O
prepared	O
at	O
72	O
hours	O
after	O
treatment	O
with	O
5	O
µM	O
DAC	O
and	O
precipitated	O
with	O
antibodies	B-GP
directed	O
against	O
IgG	B-GP
,	O
Sp1	B-GP
and	O
RNA	B-GP
pol	I-GP
II	I-GP
.	O

After	O
DNA	O
recovery	O
,	O
the	O
precipitates	O
were	O
evaluated	O
by	O
real	O
-	O
time	O
PCR	O
as	O
described	O
in	O
Experimental	O
Procedures	O
.	O

Results	O
are	O
expressed	O
as	O
fold	O
change	O
over	O
IgG	B-GP
and	O
represent	O
means	O
of	O
at	O
least	O
three	O
independent	O
experiments	O
±	O
SEM	O
(*	O
p	O
<	O
0	O
.	O
001	O
).	O

These	O
data	O
demonstrate	O
that	O
PDHA2	B-GP
gene	O
transcription	O
was	O
reactivated	O
by	O
DAC	O
treatment	O
in	O
SH	O
-	O
SY5Y	O
cells	O
,	O
suggesting	O
that	O
DNA	O
demethylation	O
may	O
play	O
a	O
pivotal	O
role	O
in	O
PDHA2	B-GP
tissue	O
-	O
specific	O
expression	O
.	O

DAC	O
induces	O
demethylation	O
of	O
PDHA2	B-GP
coding	O
region	O

In	O
order	O
to	O
confirm	O
that	O
DAC	O
can	O
induce	O
the	O
reactivation	O
of	O
PDHA2	B-GP
expression	O
in	O
SH	O
-	O
SY5Y	O
cells	O
,	O
in	O
a	O
demethylation	O
dependent	O
manner	O
,	O
we	O
analyzed	O
the	O
methylation	O
status	O
of	O
PDHA2	B-GP
gene	O
body	O
by	O
sodium	O
bisulfite	O
sequencing	O
analysis	O
.	O

Since	O
we	O
have	O
previously	O
shown	O
that	O
the	O
PDHA2	B-GP
gene	O
contains	O
two	O
CpG	O
islands	O
,	O
one	O
located	O
in	O
the	O
promoter	O
region	O
(	O
nucleotides	O
−	O
128	O
to	O
+	O
73	O
)	O
and	O
the	O
other	O
located	O
in	O
the	O
coding	O
region	O
(	O
nucleotides	O
+	O
197	O
to	O
+	O
460	O
)	O
[	O
14	O
],	O
we	O
have	O
analyzed	O
the	O
methylation	O
patterns	O
of	O
both	O
CpG	O
islands	O
.	O

In	O
accordance	O
with	O
our	O
previous	O
results	O
,	O
we	O
observed	O
that	O
the	O
CpG	O
island	O
I	O
,	O
located	O
in	O
the	O
promoter	O
region	O
,	O
is	O
fully	O
methylated	O
in	O
untreated	O
SH	O
-	O
SY5Y	O
cells	O
,	O
and	O
seems	O
to	O
be	O
insensitive	O
to	O
DAC	O
,	O
since	O
it	O
remains	O
methylated	O
after	O
treatment	O
with	O
this	O
drug	O
(	O
Fig	O
.	O
6A	O
).	O

Effectively	O
,	O
its	O
CpG	O
sites	O
remained	O
fully	O
methylated	O
not	O
only	O
after	O
DAC	O
treatment	O
,	O
but	O
after	O
TSA	O
and	O
DAC	O
plus	O
TSA	O
treatment	O
,	O
as	O
well	O
.	O

Interestingly	O
,	O
the	O
analysis	O
of	O
the	O
CpG	O
island	O
II	O
,	O
located	O
in	O
the	O
coding	O
region	O
,	O
showed	O
significant	O
demethylation	O
after	O
treatment	O
with	O
DAC	O
(	O
Table	O
S1	O
)	O
(	O
Fig	O
.	O
6A	O
and	O
6B	O
);	O
TSA	O
alone	O
had	O
no	O
effect	O
,	O
but	O
after	O
pre	O
-	O
treatment	O
with	O
DAC	O
,	O
the	O
demethylation	O
level	O
of	O
this	O
exonic	O
CpG	O
island	O
seems	O
to	O
be	O
slightly	O
increased	O
,	O
which	O
is	O
particularly	O
significant	O
in	O
the	O
CpG	O
sites	O
+	O
410	O
and	O
+	O
492	O
(	O
Tukey	O
for	O
unequal	O
N	O
,	O
p	O
<	O
0	O
.	O
01	O
)	O
(	O
Fig	O
.	O
6B	O
).	O

DNA	O
methylation	O
status	O
of	O
the	O
human	B-OG
PDHA2	B-GP
gene	O
after	O
sodium	O
bisulfite	O
PCR	O
sequencing	O
.	O

A	O
)	O
Sample	O
chromatograms	O
obtained	O
for	O
both	O
PDHA2	B-GP
CpG	O
Islands	O
,	O
before	O
and	O
after	O
treatment	O
with	O
5	O
µM	O
DAC	O
;	O
B	O
)	O
DNA	O
methylation	O
status	O
of	O
CpG	O
sites	O
in	O
the	O
CpG	O
island	O
II	O
located	O
in	O
the	O
coding	O
region	O
of	O
PDHA2	B-GP
gene	O
,	O
before	O
and	O
after	O
treatment	O
with	O
5	O
µM	O
DAC	O
for	O
96	O
h	O
and	O
/	O
or	O
0	O
.	O
25	O
µM	O
TSA	O
for	O
24	O
h	O
.	O

Results	O
represent	O
means	O
of	O
at	O
least	O
three	O
independent	O
experiments	O
±	O
SEM	O
(*	O
p	O
<	O
0	O
.	O
05	O
;	O
†	O
p	O
<	O
0	O
.	O
01	O
;	O
§	O
p	O
<	O
0	O
.	O
001	O
by	O
Tukey	O
HSD	O
for	O
unequal	O
N	O
test	O
).	O

Recently	O
,	O
several	O
potential	O
alternative	O
transcription	O
start	O
sites	O
were	O
identified	O
in	O
PDHA2	B-GP
gene	O
[	O
15	O
].	O

These	O
are	O
located	O
in	O
the	O
coding	O
region	O
encompassing	O
the	O
CpG	O
island	O
II	O
.	O

Therefore	O
,	O
one	O
could	O
hypothesize	O
that	O
demethylation	O
of	O
the	O
PDHA2	B-GP
CpG	O
island	O
II	O
corresponds	O
to	O
the	O
demethylation	O
of	O
alternative	O
promoters	O
that	O
control	O
transcription	O
of	O
truncated	O
PDHA2	B-GP
transcripts	O
.	O

Indeed	O
,	O
as	O
the	O
qPCR	O
assay	O
used	O
a	O
TaqMan	O
probe	O
hybridizing	O
to	O
the	O
3	O
′	O
UTR	O
of	O
the	O
PDHA2	B-GP
mRNA	O
,	O
the	O
presence	O
of	O
eventual	O
shorter	O
truncated	O
transcripts	O
could	O
not	O
be	O
discarded	O
.	O

Accordingly	O
,	O
we	O
further	O
analyzed	O
PDHA2	B-GP
expression	O
by	O
conventional	O
RT	O
-	O
PCR	O
with	O
a	O
set	O
of	O
specific	O
primers	O
designed	O
to	O
amplify	O
the	O
5	O
′	O
region	O
of	O
the	O
full	O
-	O
length	O
transcript	O
(	O
nucleotides	O
−	O
27	O
to	O
+	O
432	O
).	O

We	O
detected	O
the	O
expected	O
amplification	O
product	O
with	O
459	O
bp	O
only	O
in	O
DAC	O
-	O
treated	O
cells	O
,	O
which	O
proves	O
that	O
DAC	O
promotes	O
the	O
transcription	O
of	O
a	O
full	O
-	O
length	O
PDHA2	B-GP
transcript	O
(	O
Fig	O
.	O
7	O
).	O

DAC	O
activates	O
a	O
full	O
-	O
length	O
PDHA2	B-GP
transcript	O
.	O

Conventional	O
RT	O
-	O
PCR	O
analysis	O
,	O
using	O
primers	O
hybridizing	O
to	O
the	O
5	O
′	O
region	O
,	O
was	O
used	O
for	O
detection	O
of	O
PDHA2	B-GP
transcripts	O
.	O

(	O
1	O
)	O
SH	O
-	O
SY5Y	O
cells	O
before	O
treatment	O
.	O

(	O
2	O
)	O
SH	O
-	O
SY5Y	O
cells	O
after	O
treatment	O
with	O
5	O
µM	O
DAC	O
.	O

(	O
3	O
)	O
Negative	O
control	O
–	O
no	O
biological	O
sample	O
.	O

(	O
4	O
)	O
Positive	O
control	O
–	O
mature	O
spermatozoa	O
sample	O
.	O

(	O
M	O
)	O
HyperLadder	O
II	O
(	O
Bioline	O
,	O
London	O
,	O
UK	O
).	O

These	O
results	O
are	O
consistent	O
with	O
our	O
previous	O
work	O
[	O
14	O
],	O
and	O
strongly	O
suggest	O
that	O
PDHA2	B-GP
reactivation	O
in	O
somatic	O
cells	O
proceeds	O
via	O
a	O
mechanism	O
independent	O
of	O
promoter	O
demethylation	O
,	O
most	O
probably	O
dependent	O
on	O
demethylation	O
of	O
the	O
coding	O
region	O
.	O

Discussion	O

PDHA2	B-GP
gene	O
activation	O
in	O
somatic	O
tissues	O
has	O
been	O
postulated	O
as	O
a	O
conceptual	O
therapy	O
for	O
PDC	B-DS
deficiencies	I-DS
caused	O
by	O
PDHA1	B-GP
gene	O
mutations	O
[	O
5	O
],	O
[	O
16	O
].	O

Accordingly	O
,	O
it	O
is	O
crucial	O
to	O
understand	O
the	O
mechanisms	O
controlling	O
human	B-OG
PDHA2	B-GP
tissue	O
-	O
specific	O
expression	O
,	O
namely	O
what	O
factors	O
are	O
responsible	O
for	O
the	O
silencing	O
of	O
this	O
gene	O
in	O
somatic	O
tissues	O
,	O
and	O
its	O
activation	O
in	O
spermatogenic	O
ones	O
(	O
diploid	O
and	O
haploid	O
germ	O
cells	O
).	O

However	O
,	O
the	O
lack	O
of	O
a	O
suitable	O
cell	O
line	O
to	O
study	O
the	O
regulatory	O
mechanisms	O
underlying	O
PDHA2	B-GP
gene	O
expression	O
has	O
hampered	O
this	O
elucidation	O
for	O
a	O
long	O
time	O
.	O

The	O
first	O
step	O
towards	O
understanding	O
the	O
regulation	O
of	O
a	O
particular	O
gene	O
is	O
the	O
identification	O
of	O
regulatory	O
elements	O
and	O
factors	O
involved	O
in	O
basal	O
expression	O
.	O

Accordingly	O
,	O
our	O
studies	O
began	O
by	O
the	O
functional	O
analysis	O
of	O
human	B-OG
PDHA2	B-GP
promoter	O
.	O

The	O
results	O
showed	O
that	O
PDHA2	B-GP
promoter	O
-	O
directed	O
transcription	O
of	O
the	O
luciferase	B-GP
reporter	O
gene	O
occurred	O
in	O
cultured	O
somatic	O
cells	O
(	O
HeLa	O
,	O
NT2	O
and	O
SH	O
-	O
SY5Y	O
),	O
where	O
PDHA2	B-GP
mRNA	O
is	O
undetectable	O
.	O

Deletion	O
analysis	O
further	O
revealed	O
that	O
the	O
region	O
spanning	O
from	O
−	O
122	O
to	O
−	O
6	O
is	O
indispensable	O
for	O
basal	O
expression	O
of	O
this	O
TATA	O
-	O
less	O
promoter	O
.	O

Moreover	O
,	O
and	O
in	O
each	O
cell	O
line	O
,	O
no	O
significant	O
differences	O
were	O
found	O
among	O
the	O
reporter	O
gene	O
activities	O
driven	O
by	O
all	O
the	O
other	O
PDHA2	B-GP
deletion	O
promoter	O
constructs	O
.	O

Additionally	O
,	O
each	O
construct	O
displayed	O
comparable	O
reporter	O
activities	O
in	O
the	O
three	O
different	O
somatic	O
cell	O
lines	O
.	O

These	O
observations	O
suggested	O
that	O
the	O
mechanisms	O
involved	O
in	O
the	O
repression	O
of	O
PDHA2	B-GP
expression	O
in	O
somatic	O
cells	O
are	O
not	O
operative	O
when	O
the	O
core	O
promoter	O
or	O
the	O
5	O
′	O
flanking	O
region	O
are	O
transiently	O
transfected	O
into	O
somatic	O
cells	O
.	O

Moreover	O
,	O
these	O
results	O
corroborated	O
the	O
previous	O
transactivation	O
experiments	O
described	O
by	O
Datta	O
and	O
colleagues	O
[	O
5	O
],	O
who	O
also	O
observed	O
PDHA2	B-GP
promoter	O
-	O
directed	O
transcription	O
in	O
human	B-OG
hepatocellular	B-DS
carcinoma	I-DS
cells	O
.	O

However	O
,	O
we	O
could	O
not	O
replicate	O
their	O
results	O
concerning	O
the	O
detection	O
of	O
several	O
enhancer	O
and	O
repressor	O
elements	O
,	O
because	O
no	O
significant	O
differences	O
in	O
luciferase	B-GP
reporter	O
activities	O
were	O
detected	O
between	O
the	O
various	O
deletion	O
constructs	O
.	O

Additionally	O
,	O
the	O
same	O
authors	O
suggested	O
the	O
existence	O
of	O
a	O
putative	O
Sp	O
responsive	O
element	O
that	O
would	O
be	O
important	O
for	O
Sp1	B-GP
-	O
dependent	O
transcription	O
initiation	O
[	O
5	O
].	O

However	O
,	O
our	O
chromatin	O
immunoprecipitation	O
assays	O
did	O
not	O
demonstrate	O
any	O
binding	O
of	O
Sp1	B-GP
transcription	B-GP
factors	I-GP
to	O
the	O
proximal	O
promoter	O
of	O
the	O
PDHA2	B-GP
gene	O
.	O

Additionally	O
,	O
and	O
more	O
importantly	O
,	O
our	O
observation	O
that	O
PDHA2	B-GP
promoter	O
reporter	O
constructs	O
presented	O
high	O
luciferase	B-GP
activity	O
in	O
all	O
somatic	O
cell	O
lines	O
,	O
where	O
the	O
PDHA2	B-GP
mRNA	O
cannot	O
be	O
detected	O
,	O
reinforces	O
the	O
idea	O
that	O
PDHA2	B-GP
tissue	O
-	O
specific	O
expression	O
may	O
be	O
under	O
strict	O
control	O
of	O
epigenetic	O
mechanisms	O
of	O
regulation	O
.	O

Furthermore	O
,	O
in	O
vitro	O
methylation	O
of	O
PDHA2	B-GP
promoter	O
constructs	O
with	O
SssI	B-GP
methylase	I-GP
resulted	O
in	O
a	O
complete	O
abrogation	O
of	O
luciferase	B-GP
activity	O
.	O

Our	O
next	O
approach	O
was	O
to	O
further	O
explore	O
the	O
involvement	O
of	O
epigenetics	O
,	O
namely	O
DNA	O
methylation	O
and	O
/	O
or	O
histone	B-GP
modifications	O
,	O
on	O
the	O
regulation	O
of	O
PDHA2	B-GP
gene	O
expression	O
.	O

The	O
results	O
showed	O
that	O
treatment	O
of	O
SH	O
-	O
SY5Y	O
cell	O
cultures	O
with	O
DAC	O
induced	O
PDHA2	B-GP
derepression	O
with	O
a	O
concomitant	O
accumulation	O
of	O
PDHA2	B-GP
transcript	O
.	O

On	O
the	O
other	O
hand	O
,	O
inhibition	O
of	O
histone	B-GP
deacetylation	O
did	O
not	O
elicit	O
any	O
induction	O
of	O
PDHA2	B-GP
expression	O
,	O
nor	O
did	O
it	O
potentiate	O
the	O
DAC	O
effect	O
.	O

Moreover	O
,	O
the	O
accumulation	O
of	O
the	O
PDHA2	B-GP
mRNA	O
after	O
DAC	O
treatment	O
was	O
correlated	O
with	O
an	O
enrichment	O
of	O
RNA	B-GP
pol	I-GP
II	I-GP
at	O
the	O
PDHA2	B-GP
proximal	O
promoter	O
(+	O
1	O
bp	O
region	O
),	O
which	O
likely	O
triggers	O
the	O
observed	O
increase	O
in	O
PDHA2	B-GP
mRNA	O
levels	O
.	O

The	O
fact	O
that	O
treatment	O
with	O
DAC	O
alone	O
elicited	O
a	O
significant	O
effect	O
upon	O
PDHA2	B-GP
gene	O
expression	O
suggests	O
that	O
changes	O
associated	O
with	O
methylation	O
are	O
sufficient	O
to	O
drive	O
transcription	O
initiation	O
of	O
this	O
testis	O
-	O
specific	O
gene	O
in	O
somatic	O
cells	O
.	O

Once	O
proved	O
that	O
DAC	O
was	O
able	O
to	O
induce	O
PDHA2	B-GP
gene	O
expression	O
in	O
cultured	O
somatic	O
cells	O
,	O
it	O
would	O
be	O
important	O
to	O
investigate	O
the	O
methylation	O
status	O
of	O
this	O
gene	O
,	O
before	O
and	O
after	O
treatment	O
with	O
the	O
demethylating	O
drug	O
,	O
in	O
order	O
to	O
assure	O
that	O
demethylation	O
was	O
underlying	O
PDHA2	B-GP
transcription	O
.	O

Our	O
results	O
demonstrated	O
that	O
DAC	O
promoted	O
a	O
relevant	O
demethylation	O
of	O
PDHA2	B-GP
coding	O
region	O
,	O
which	O
was	O
fully	O
methylated	O
before	O
treatment	O
.	O

However	O
,	O
the	O
promoter	O
CpG	O
island	O
I	O
remained	O
fully	O
methylated	O
,	O
suggesting	O
its	O
insensibility	O
to	O
demethylation	O
,	O
at	O
least	O
by	O
DAC	O
treatment	O
in	O
the	O
tested	O
conditions	O
.	O

These	O
findings	O
corroborate	O
our	O
previous	O
reported	O
results	O
,	O
where	O
we	O
observed	O
that	O
PDHA2	B-GP
expressing	O
tissues	O
(	O
i	O
.	O
e	O
spermatogenic	O
cells	O
)	O
presented	O
the	O
coding	O
region	O
completely	O
demethylated	O
,	O
while	O
non	O
-	O
expressing	O
tissues	O
displayed	O
it	O
fully	O
methylated	O
[	O
14	O
].	O

Moreover	O
,	O
these	O
results	O
also	O
correlate	O
with	O
our	O
recent	O
finding	O
concerning	O
a	O
family	O
displaying	O
PDHA2	B-GP
gene	O
expression	O
in	O
somatic	O
tissues	O
[	O
17	O
],	O
an	O
interesting	O
case	O
that	O
may	O
configure	O
the	O
previously	O
referred	O
long	O
dreamed	O
therapy	O
for	O
PDC	B-DS
deficiency	I-DS
,	O
i	O
.	O
e	O
.	O
the	O
somatic	O
activation	O
of	O
PDHA2	B-GP
expression	O
.	O

The	O
results	O
obtained	O
either	O
then	O
by	O
in	O
-	O
vivo	O
or	O
now	O
by	O
ex	O
-	O
vivo	O
experiments	O
are	O
overlapping	O
;	O
actually	O
,	O
both	O
methylation	O
analyses	O
revealed	O
a	O
correlation	O
between	O
demethylation	O
of	O
the	O
coding	O
region	O
and	O
PDHA2	B-GP
derepression	O
.	O

Moreover	O
,	O
and	O
interestingly	O
,	O
the	O
level	O
of	O
demethylation	O
in	O
the	O
coding	O
region	O
is	O
very	O
similar	O
in	O
samples	O
derived	O
from	O
the	O
cultured	O
cells	O
treated	O
with	O
DAC	O
and	O
from	O
the	O
family	O
individuals	O
.	O

However	O
,	O
Yamashita	O
and	O
colleagues	O
[	O
15	O
]	O
recently	O
identified	O
multiple	O
transcriptional	O
start	O
sites	O
downstream	O
of	O
the	O
canonical	O
one	O
(+	O
248	O
,	O
+	O
253	O
and	O
+	O
269	O
),	O
which	O
are	O
located	O
precisely	O
within	O
the	O
CpG	O
island	O
II	O
region	O
(	O
nucleotides	O
+	O
197	O
to	O
+	O
460	O
).	O

Accordingly	O
,	O
this	O
region	O
could	O
eventually	O
harbor	O
alternative	O
promoter	O
that	O
would	O
trigger	O
the	O
transcription	O
of	O
truncated	O
PDHA2	B-GP
mRNAs	O
.	O

However	O
,	O
our	O
RT	O
-	O
PCR	O
results	O
clearly	O
show	O
that	O
DAC	O
induces	O
transcription	O
of	O
full	O
-	O
length	O
transcripts	O
.	O

These	O
data	O
are	O
corroborated	O
by	O
the	O
significant	O
enrichment	O
of	O
RNA	B-GP
pol	I-GP
II	I-GP
at	O
the	O
proximal	O
promoter	O
.	O

Taken	O
together	O
,	O
our	O
results	O
confirm	O
that	O
methylation	O
of	O
the	O
coding	O
region	O
is	O
a	O
key	O
point	O
in	O
somatic	O
cell	O
silencing	O
of	O
PDHA2	B-GP
gene	O
.	O

Actually	O
,	O
DNA	O
methylation	O
appears	O
to	O
be	O
particularly	O
suitable	O
for	O
the	O
regulation	O
of	O
germ	O
line	O
-	O
specific	O
genes	O
,	O
and	O
this	O
is	O
probably	O
related	O
to	O
the	O
global	O
demethylation	O
process	O
that	O
occurs	O
during	O
the	O
development	O
of	O
spermatogenic	O
cells	O
,	O
which	O
may	O
provide	O
the	O
mechanism	O
by	O
which	O
these	O
germ	O
line	O
-	O
specific	O
genes	O
are	O
demethylated	O
[	O
18	O
],	O
[	O
19	O
].	O

And	O
,	O
despite	O
the	O
fact	O
that	O
DNA	O
methylation	O
does	O
not	O
seem	O
to	O
be	O
the	O
primary	O
control	O
mechanism	O
regulating	O
the	O
programmed	O
expression	O
of	O
most	O
tissue	O
-	O
specific	O
genes	O
resulting	O
in	O
tissue	O
differentiation	O
,	O
there	O
are	O
several	O
examples	O
that	O
indicate	O
that	O
DNA	O
methylation	O
can	O
serve	O
as	O
the	O
primary	O
control	O
mechanism	O
for	O
the	O
expression	O
of	O
a	O
number	O
of	O
germ	O
line	O
-	O
specific	O
genes	O
[	O
20	O
],	O
[	O
21	O
],	O
[	O
22	O
].	O

Although	O
the	O
expression	O
of	O
previously	O
referred	O
genes	O
proceeds	O
via	O
a	O
promoter	O
methylation	O
-	O
dependent	O
mechanism	O
,	O
we	O
also	O
can	O
find	O
in	O
the	O
literature	O
some	O
references	O
to	O
human	B-OG
genes	O
that	O
are	O
regulated	O
by	O
methylation	O
of	O
the	O
coding	O
region	O
,	O
namely	O
monocarboxylate	B-GP
transporter	I-GP
MCT3	B-GP
[	O
23	O
].	O

Another	O
particular	O
interesting	O
example	O
is	O
the	O
mouse	B-OG
Tact1	B-GP
/	O
Actl7	B-GP
gene	O
[	O
24	O
],	O
which	O
is	O
also	O
intronless	O
and	O
testis	O
-	O
specific	O
,	O
like	O
the	O
PDHA2	B-GP
gene	O
.	O

Indeed	O
,	O
it	O
has	O
already	O
been	O
described	O
that	O
methylation	O
of	O
the	O
coding	O
region	O
,	O
per	O
se	O
,	O
can	O
control	O
gene	O
expression	O
by	O
preventing	O
promoter	O
activity	O
at	O
the	O
level	O
of	O
the	O
chromatin	O
structure	O
.	O

Indeed	O
,	O
CpG	O
methylation	O
induces	O
a	O
local	O
repressive	O
chromatin	O
structure	O
,	O
mediated	O
by	O
the	O
binding	O
of	O
methyl	B-GP
-	I-GP
CpG	I-GP
binding	I-GP
domain	I-GP
(	I-GP
MBD	I-GP
)	I-GP
proteins	I-GP
which	O
recruit	O
other	O
proteins	O
including	O
sin3A	B-GP
and	O
histone	B-GP
deacetylase	I-GP
;	O
when	O
a	O
sufficient	O
amount	O
of	O
CpGs	O
is	O
methylated	O
,	O
this	O
repression	O
is	O
transmissible	O
in	O
cis	O
,	O
spreading	O
for	O
several	O
hundred	O
base	O
pairs	O
[	O
25	O
],	O
[	O
26	O
],	O
[	O
27	O
].	O

Accordingly	O
,	O
more	O
or	O
less	O
distant	O
methylated	O
sequences	O
,	O
like	O
the	O
PDHA2	B-GP
coding	O
region	O
,	O
can	O
promote	O
gene	O
repression	O
.	O

Interestingly	O
,	O
and	O
as	O
stated	O
by	O
Nan	O
and	O
co	O
-	O
workers	O
,	O
this	O
type	O
of	O
repression	O
is	O
greater	O
if	O
the	O
promoter	O
itself	O
is	O
methylated	O
[	O
28	O
],	O
which	O
is	O
the	O
case	O
of	O
PDHA2	B-GP
promoter	O
.	O

Furthermore	O
,	O
it	O
has	O
also	O
been	O
postulated	O
that	O
methylation	O
of	O
the	O
coding	O
region	O
can	O
inhibit	O
gene	O
expression	O
by	O
interfering	O
with	O
the	O
elongation	O
step	O
rather	O
than	O
with	O
transcription	O
initiation	O
,	O
by	O
causing	O
RNA	B-GP
pol	I-GP
II	I-GP
to	O
pause	O
or	O
to	O
prematurely	O
terminate	O
[	O
29	O
],	O
[	O
30	O
].	O

Moreover	O
,	O
the	O
inhibitory	O
effect	O
upon	O
elongation	O
is	O
prominent	O
when	O
methylation	O
occurs	O
near	O
the	O
start	O
codon	O
[	O
31	O
].	O

Based	O
on	O
this	O
hypothesis	O
,	O
we	O
attempted	O
to	O
explore	O
elongation	O
of	O
PDHA2	B-GP
transcription	O
by	O
chromatin	O
immunoprecipitation	O
assays	O
.	O

The	O
results	O
did	O
not	O
show	O
any	O
particular	O
differences	O
in	O
the	O
chromatin	O
recovered	O
before	O
and	O
after	O
DAC	O
treatment	O
,	O
namely	O
when	O
using	O
the	O
elongation	O
marker	O
H3K36me3	O
.	O

A	O
recent	O
report	O
has	O
shown	O
a	O
clear	O
correlation	O
between	O
H3K36me3	O
marking	O
and	O
transcriptional	O
activity	O
in	O
intron	O
-	O
containing	O
genes	O
;	O
however	O
,	O
in	O
intronless	O
genes	O
H3K36me3	O
is	O
detected	O
at	O
much	O
lower	O
levels	O
irrespective	O
of	O
expression	O
levels	O
[	O
32	O
].	O

Indeed	O
,	O
there	O
are	O
other	O
examples	O
showing	O
that	O
transcriptional	O
elongation	O
is	O
differently	O
controlled	O
in	O
intronless	O
genes	O
when	O
compared	O
to	O
longer	O
intron	O
-	O
containing	O
genes	O
[	O
33	O
].	O

Accordingly	O
,	O
because	O
PDHA2	B-GP
gene	O
lacks	O
introns	O
,	O
different	O
approaches	O
need	O
to	O
be	O
designed	O
.	O

In	O
summary	O
,	O
we	O
hypothesize	O
that	O
PDHA2	B-GP
gene	O
belongs	O
not	O
only	O
to	O
a	O
restricted	O
group	O
of	O
germ	O
line	O
-	O
specific	O
genes	O
that	O
use	O
DNA	O
methylation	O
as	O
a	O
primary	O
silencing	O
mechanism	O
,	O
but	O
to	O
a	O
unique	O
subset	O
of	O
those	O
genes	O
whose	O
expression	O
is	O
regulated	O
by	O
the	O
methylation	O
status	O
of	O
the	O
coding	O
region	O
.	O

Furthermore	O
,	O
these	O
new	O
insights	O
on	O
the	O
regulatory	O
mechanism	O
underlying	O
PDHA2	B-GP
tissue	O
-	O
specific	O
expression	O
may	O
open	O
potential	O
therapeutic	O
avenues	O
for	O
PDC	B-DS
deficiency	I-DS
caused	O
by	O
PDHA1	B-GP
mutations	O
.	O

Materials	O
and	O
Methods	O

Cloning	O
the	O
human	B-OG
PDHA2	B-GP
gene	O

Two	O
different	O
fragments	O
of	O
the	O
human	B-OG
PDHA2	B-GP
gene	O
(	O
GenBank	O
ID	O
:	O
M86808	O
)	O
were	O
cloned	O
in	O
pCR	O
®	O
4Blunt	O
-	O
TOPO	O
®	O
vector	O
(	O
Invitrogen	O
Corporation	O
,	O
Carlsbad	O
,	O
CA	O
,	O
USA	O
)	O
after	O
PCR	O
amplification	O
with	O
Platinum	O
®	O
Pfx	O
Polymerase	B-GP
(	O
Invitrogen	O
)	O
of	O
genomic	O
DNA	O
isolated	O
from	O
circulating	O
lymphocytes	O
of	O
a	O
healthy	O
individual	O
.	O

The	O
first	O
fragment	O
harboring	O
the	O
PDHA2	B-GP
promoter	O
region	O
(	O
nucleotides	O
−	O
980	O
to	O
−	O
6	O
)	O
was	O
amplified	O
using	O
the	O
primers	O
pPDHA2	O
-	O
975	O
bp	O
and	O
pPDHA2	O
-	O
R	O
listed	O
in	O
Table	O
1	O
.	O

The	O
second	O
fragment	O
designed	O
to	O
harbor	O
both	O
CpG	O
islands	O
of	O
PDHA2	B-GP
gene	O
(−	O
274	O
to	O
+	O
487	O
)	O
was	O
amplified	O
with	O
pPDHA2	O
-	O
269	O
bp	O
and	O
PDHA2	B-GP
.	O
CpGs	O
-	O
R	O
primers	O
(	O
Table	O
1	O
).	O

The	O
recombinant	O
plasmids	O
were	O
sequenced	O
by	O
primer	O
walking	O
and	O
named	O
pPDHA2	O
-	O
TOPO	O
and	O
PDHA2	B-GP
.	O
CpGs	O
-	O
TOPO	O
,	O
respectively	O
.	O

For	O
sequence	O
numbering	O
,	O
nucleotide	O
+	O
1	O
was	O
assigned	O
to	O
the	O
adenosine	O
of	O
the	O
initiation	O
translation	O
codon	O
ATG	O
.	O

Sequence	O
of	O
oligonucleotides	O
used	O
in	O
the	O
human	B-OG
PDHA2	B-GP
gene	O
cloning	O
.	O

Oligonucleotides	O

Sequence	O
(	O
5	O
′→	O
3	O
′)	O

pPDHA2	O
–	O
R	O

TCACGGAGTGCTGTAGATGGCTCGAGCCG	O

pPDHA2	O
–	O
975	O
bp	O

TGGAAACCTGCTGAAGACATT	O

pPDHA2	O
–	O
833	O
bp	O

AAGGAAAAGTGGAATGTCACAAA	O

pPDHA2	O
–	O
695	O
bp	O

ATACATTTTCCCTCCCCACT	O

pPDHA2	O
–	O
591	O
bp	O

GTTAACGTGCGTGTGCTTGT	O

pPDHA2	O
–	O
506	O
bp	O

GGCACATTATGGAGCAGGAT	O

pPDHA2	O
–	O
436	O
bp	O

TGGTAGGAAGAAATACCTTTGGA	O

pPDHA2	O
–	O
349	O
bp	O

TTGTCGGGAAAGCTTGAGAT	O

pPDHA2	O
–	O
269	O
bp	O

GCGATTAGGATGCCCTGTAG	O

pPDHA2	O
–	O
196	O
bp	O

GGCAGGCACTGTACAAATCA	O

PDHA2	B-GP
.	O
CpGs	O
–	O
R	O

CGGCTCGAGCCATTGCCCCCATAGAAGT	O

PDHA2	B-GP
promoter	O
reporter	O
constructs	O

Several	O
different	O
fragments	O
derived	O
from	O
the	O
human	B-OG
PDHA2	B-GP
promoter	O
region	O
were	O
subcloned	O
into	O
the	O
luciferase	B-GP
expression	O
vector	O
pGL2	O
-	O
Basic	O
vector	O
(	O
Promega	O
Corporation	O
,	O
Madison	O
,	O
WI	O
USA	O
).	O

We	O
used	O
the	O
pPDHA2	O
-	O
TOPO	O
plasmid	O
as	O
a	O
template	O
to	O
amplify	O
fragments	O
of	O
different	O
lengths	O
,	O
using	O
different	O
forward	O
primers	O
and	O
a	O
reverse	O
primer	O
,	O
which	O
contains	O
a	O
XhoI	B-GP
overhang	O
site	O
,	O
listed	O
in	O
Table	O
1	O
.	O

The	O
PCR	O
products	O
,	O
amplified	O
with	O
the	O
Platinum	O
®	O
Pfx	O
Polymerase	B-GP
(	O
Invitrogen	O
),	O
were	O
subcloned	O
in	O
the	O
pGL2	O
reporter	O
plasmid	O
into	O
SmaI	B-GP
/	O
XhoI	B-GP
sites	O
generating	O
plasmids	O
975	O
.	O
pGL2	O
(−	O
980	O
to	O
−	O
6	O
),	O
833	O
.	O
pGL2	O
(−	O
838	O
to	O
−	O
6	O
),	O
695	O
.	O
pGL2	O
(−	O
700	O
to	O
−	O
6	O
),	O
591	O
.	O
pGL2	O
(−	O
596	O
to	O
−	O
6	O
),	O
506	O
.	O
pGL2	O
(−	O
511	O
to	O
−	O
6	O
),	O
436	O
.	O
pGL2	O
(−	O
441	O
to	O
−	O
6	O
),	O
349	O
.	O
pGL2	O
(−	O
354	O
to	O
−	O
6	O
),	O
269	O
.	O
pGL2	O
(−	O
274	O
to	O
−	O
6	O
),	O
and	O
196	O
.	O
pGL2	O
(−	O
201	O
to	O
−	O
6	O
).	O

The	O
pPDHA2	O
-	O
TOPO	O
recombinant	O
was	O
also	O
digested	O
with	O
enzymes	O
MslI	B-GP
/	O
XhoI	B-GP
and	O
the	O
117	O
bp	O
fragment	O
was	O
subcloned	O
in	O
the	O
pGL2	O
reporter	O
plasmid	O
generating	O
the	O
117	O
.	O
pGL2	O
recombinant	O
(−	O
122	O
to	O
−	O
6	O
).	O

An	O
ultimate	O
PDHA2	B-GP
reporter	O
construct	O
was	O
subcloned	O
into	O
the	O
pGL2	O
-	O
Basic	O
vector	O
,	O
using	O
as	O
template	O
the	O
PDHA2	B-GP
.	O
CpGs	O
-	O
TOPO	O
plasmid	O
.	O

This	O
reporter	O
construct	O
was	O
named	O
CpGs	O
.	O
pGL2	O
and	O
harbored	O
both	O
CpGs	O
islands	O
present	O
in	O
PDHA2	B-GP
gene	O
.	O

In	O
vitro	O
methylation	O
of	O
PDHA2	B-GP
constructs	O

M	B-GP
.	I-GP
SssI	I-GP
was	O
used	O
to	O
methylate	O
the	O
CpG	O
dinucleotides	O
of	O
the	O
PDHA2	B-GP
gene	O
/	O
luciferase	B-GP
reporter	O
constructs	O
or	O
the	O
pGL2	O
basic	O
vector	O
,	O
based	O
on	O
the	O
protocol	O
of	O
the	O
manufacturer	O
(	O
New	O
England	O
Biolabs	O
,	O
Beverly	O
,	O
MA	O
).	O

Mock	O
reactions	O
were	O
carried	O
out	O
in	O
parallel	O
without	O
adding	O
the	O
methylase	B-GP
.	O

The	O
samples	O
were	O
then	O
incubated	O
with	O
methylation	O
-	O
sensitive	O
restriction	B-GP
enzyme	I-GP
HpaII	B-GP
,	O
followed	O
by	O
agarose	O
gel	O
electrophoresis	O
.	O

Complete	O
methylation	O
of	O
the	O
CpG	O
sites	O
of	O
the	O
constructs	O
was	O
verified	O
by	O
protection	O
of	O
the	O
methylated	O
DNA	O
from	O
digestion	O
by	O
this	O
enzyme	O
.	O

Methylated	O
and	O
mock	O
-	O
treated	O
plasmids	O
were	O
purified	O
with	O
a	O
QIAquick	O
gel	O
extraction	O
kit	O
(	O
Qiagen	O
,	O
Hilden	O
,	O
Germany	O
)	O
and	O
used	O
for	O
reporter	O
gene	O
analyses	O
after	O
transient	O
transfection	O
in	O
somatic	O
cell	O
lines	O
.	O

Transactivation	O
studies	O

The	O
basal	O
promoter	O
activity	O
of	O
the	O
different	O
reporter	O
plasmids	O
was	O
assayed	O
by	O
measuring	O
the	O
luciferase	B-GP
activity	O
after	O
transient	O
transfection	O
in	O
HeLa	O
,	O
SH	O
-	O
SY5Y	O
and	O
Ntera2	O
/	O
clone	O
D1	O
(	O
NT2	O
)	O
cell	O
lines	O
.	O

To	O
minimize	O
variations	O
in	O
transfection	O
efficiency	O
,	O
replicates	O
were	O
transfected	O
in	O
single	O
batch	O
suspension	O
with	O
FuGENE	O
®	O
HD	O
(	O
Roche	O
Diagnostics	O
GmbH	O
,	O
Penzberg	O
,	O
Germany	O
)	O
according	O
to	O
the	O
manufacturer	O
'	O
s	O
instructions	O
.	O

Plates	O
containing	O
200	O
,	O
000	O
cells	O
were	O
co	O
-	O
transfected	O
with	O
0	O
.	O
5	O
µg	O
of	O
the	O
reporter	O
plasmid	O
together	O
with	O
an	O
expression	O
plasmid	O
containing	O
the	O
β	B-GP
-	I-GP
galactosidase	I-GP
gene	O
-	O
coding	O
region	O
(	O
pSV40	O
-	O
βGAL	B-GP
).	O

Cells	O
were	O
inoculated	O
in	O
24	O
-	O
well	O
plates	O
and	O
maintained	O
for	O
48	O
h	O
.	O

These	O
cells	O
were	O
harvested	O
and	O
lysed	O
in	O
reporter	O
lysis	O
buffer	O
(	O
Promega	O
).	O

Cell	O
extracts	O
were	O
assayed	O
for	O
luciferase	B-GP
and	O
β	B-GP
-	I-GP
galactosidase	I-GP
activity	O
(	O
β	B-GP
-	I-GP
Gal	I-GP
Reporter	O
Gene	O
Assay	O
,	O
Roche	O
),	O
which	O
was	O
used	O
to	O
normalize	O
the	O
results	O
.	O

All	O
experiments	O
were	O
performed	O
at	O
least	O
three	O
times	O
in	O
duplicate	O
well	O
.	O

Cell	O
cultures	O
and	O
treatments	O

SH	O
-	O
SY5Y	O
(	O
human	B-OG
neuroblastoma	B-DS
,	O
ATCC	O
CRL	O
-	O
2266	O
)	O
cell	O
line	O
was	O
maintained	O
in	O
low	O
glucose	O
Dulbecco	O
'	O
s	O
modified	O
Eagle	O
'	O
s	O
medium	O
(	O
Sigma	O
-	O
Aldrich	O
Inc	O
.,	O
St	O
.	O
Louis	O
,	O
MO	O
,	O
USA	O
),	O
while	O
HeLa	O
(	O
human	B-OG
cervix	B-DS
adenocarcinoma	I-DS
,	O
ATCC	O
CCL	O
-	O
2	O
)	O
and	O
NT2	O
(	O
human	B-OG
teratocarcinoma	B-DS
,	O
ATCC	O
CRL	O
-	O
1973	O
)	O
cell	O
lines	O
were	O
cultured	O
in	O
high	O
glucose	O
Dulbecco	O
'	O
s	O
modified	O
Eagle	O
'	O
s	O
medium	O
(	O
Sigma	O
).	O

All	O
media	O
were	O
supplemented	O
with	O
10	O
%	O
heat	O
inactivated	O
fetal	O
bovine	O
serum	O
(	O
Biochrom	O
AG	O
,	O
Berlin	O
,	O
Germany	O
),	O
2	O
mM	O
L	O
-	O
glutamine	O
(	O
Sigma	O
),	O
100	O
units	O
/	O
mL	O
penicillin	O
and	O
100	O
mg	O
/	O
mL	O
streptomycin	O
(	O
Sigma	O
),	O
with	O
the	O
exception	O
of	O
NT2	O
culture	O
medium	O
that	O
was	O
supplemented	O
with	O
4	O
mM	O
L	O
-	O
glutamine	O
.	O

All	O
cell	O
cultures	O
were	O
carried	O
out	O
at	O
37	O
°	O
C	O
in	O
humidified	O
5	O
%	O
CO2	O
.	O

Dose	O
response	O
assays	O
of	O
5	O
-	O
Aza	O
-	O
2	O
′-	O
deoxycytidine	O
(	O
DAC	O
)	O
and	O
Trichostatin	O
A	O
(	O
TSA	O
)	O
were	O
performed	O
as	O
stated	O
in	O
Milagre	O
and	O
collaborators	O
(	O
2008	O
)	O
[	O
34	O
].	O

Subsequently	O
,	O
cells	O
were	O
treated	O
with	O
5	O
µM	O
DAC	O
and	O
0	O
.	O
25	O
µM	O
TSA	O
for	O
the	O
indicated	O
periods	O
(	O
or	O
vehicle	O
as	O
control	O
)	O
and	O
every	O
24	O
hours	O
the	O
medium	O
was	O
changed	O
.	O

RNA	O
isolation	O
and	O
qPCR	O
for	O
PDHA2	B-GP
expression	O
analysis	O

Total	O
RNA	O
was	O
prepared	O
from	O
all	O
cells	O
,	O
treated	O
and	O
untreated	O
,	O
using	O
the	O
RNeasy	O
®	O
Mini	O
Kit	O
(	O
Qiagen	O
)	O
and	O
contamination	O
by	O
genomic	O
DNA	O
was	O
eliminated	O
from	O
each	O
RNA	O
sample	O
by	O
pre	O
-	O
treatment	O
with	O
DNase	B-GP
I	I-GP
using	O
RNase	B-GP
-	O
free	O
DNase	B-GP
Set	O
(	O
Qiagen	O
).	O

Total	O
RNA	O
was	O
reverse	O
transcribed	O
using	O
the	O
Reverse	O
Transcription	O
System	O
A3500	O
Kit	O
(	O
Promega	O
)	O
with	O
random	O
primers	O
following	O
the	O
manufacturer	O
'	O
s	O
instructions	O
.	O

First	O
strand	O
DNA	O
(	O
1	O
µg	O
)	O
was	O
used	O
as	O
template	O
for	O
quantitative	O
real	O
-	O
time	O
PCR	O
with	O
an	O
ABI	O
PRISM	O
7300	O
sequence	O
detection	O
system	O
(	O
Applied	O
Biosystems	O
).	O

The	O
cycling	O
conditions	O
were	O
95	O
°	O
C	O
/	O
10	O
min	O
followed	O
by	O
40	O
cycles	O
of	O
95	O
°	O
C	O
/	O
15	O
sec	O
and	O
60	O
°	O
C	O
/	O
1	O
min	O
.	O

It	O
was	O
used	O
the	O
TaqMan	O
®	O
Gene	O
Expression	O
Assay	O
-	O
ID	O
:	O
Hs01043024_s1	O
(	O
Applied	O
Biosystems	O
)	O
for	O
specific	O
detection	O
of	O
PDHA2	B-GP
mRNA	O
,	O
and	O
the	O
TaqMan	O
®	O
β	B-GP
-	I-GP
actin	I-GP
Control	O
Reagents	O
as	O
endogenous	O
control	O
(	O
Applied	O
Biosystems	O
).	O

In	O
every	O
reaction	O
we	O
used	O
the	O
TaqMan	O
®	O
Gene	O
Expression	O
Master	O
Mix	O
(	O
Applied	O
Biosystems	O
)	O
following	O
enclosed	O
instructions	O
.	O

Each	O
sample	O
was	O
assayed	O
in	O
triplicate	O
and	O
results	O
show	O
a	O
minimum	O
of	O
three	O
independent	O
experiments	O
.	O

Transcript	O
levels	O
were	O
normalized	O
to	O
β	B-GP
-	I-GP
actin	I-GP
and	O
expressed	O
in	O
pg	O
PDHA2	B-GP
mRNA	O
per	O
ng	O
of	O
β	B-GP
-	I-GP
actin	I-GP
mRNA	O
.	O

Additionally	O
,	O
we	O
analyzed	O
PDHA2	B-GP
mRNA	O
by	O
conventional	O
RT	O
-	O
PCR	O
analysis	O
with	O
a	O
gene	O
specific	O
set	O
of	O
primers	O
,	O
designed	O
to	O
amplify	O
the	O
5	O
′	O
region	O
of	O
the	O
transcript	O
:	O
the	O
forward	O
primer	O
5	O
′-	O
TGCCATCTACAGCACTCCGT	O
-	O
3	O
′	O
hybridizing	O
to	O
nucleotides	O
−	O
27	O
to	O
−	O
8	O
and	O
the	O
reverse	O
primer	O
5	O
′-	O
AGCACAACCTCCTCTTCTTCC	O
-	O
3	O
′	O
hybridizing	O
to	O
nucleotides	O
+	O
412	O
to	O
+	O
432	O
.	O

The	O
459	O
pb	O
product	O
was	O
amplified	O
with	O
SYBR	O
green	O
Master	O
Mix	O
in	O
an	O
ABI	O
7300	O
sequence	O
detection	O
system	O
(	O
Applied	O
Biosystems	O
)	O
and	O
visualized	O
by	O
agarose	O
gel	O
electrophoresis	O
.	O

Genomic	O
DNA	O
isolation	O
and	O
bisulfite	O
sequencing	O
for	O
PDHA2	B-GP
methylation	O
analysis	O

Genomic	O
DNA	O
was	O
isolated	O
from	O
treated	O
and	O
untreated	O
cells	O
using	O
a	O
salting	O
-	O
out	O
method	O
(	O
Citogene	O
®	O
DNA	O
Blood	O
Kit	O
–	O
Citomed	O
,	O
Lisbon	O
,	O
Portugal	O
).	O

The	O
number	O
and	O
distribution	O
of	O
scattered	O
CpG	O
sites	O
and	O
CpG	O
islands	O
of	O
PDHA2	B-GP
gene	O
has	O
been	O
previously	O
analyzed	O
[	O
14	O
]	O
using	O
the	O
online	O
program	O
MethPrimer	O
,	O
available	O
at	O
www	O
.	O
urogene	O
.	O
org	O
/	O
methprimer	O
,	O
which	O
defines	O
CpG	O
islands	O
as	O
sequences	O
longer	O
than	O
200	O
bp	O
,	O
with	O
a	O
calculated	O
CG	O
composition	O
>	O
50	O
%	O
and	O
an	O
observed	O
to	O
expected	O
CpG	O
ratio	O
of	O
>	O
0	O
.	O
6	O
[	O
35	O
].	O

Bisulfite	O
PCR	O
sequencing	O
was	O
carried	O
out	O
using	O
the	O
EpiTect	O
®	O
Bisulfite	O
Kit	O
(	O
Qiagen	O
)	O
and	O
CpG	O
islands	O
were	O
amplified	O
by	O
PCR	O
using	O
the	O
specific	O
primers	O
and	O
the	O
conditions	O
previously	O
described	O
[	O
14	O
].	O

The	O
reaction	O
products	O
were	O
purified	O
by	O
MinElute	O
®	O
PCR	O
Purification	O
Kit	O
(	O
Qiagen	O
)	O
and	O
sequenced	O
in	O
both	O
directions	O
by	O
primer	O
walking	O
with	O
ABI	O
Prism	O
BigDye	O
Terminator	O
Cycle	O
Sequencing	O
Ready	O
Reaction	O
Kits	O
,	O
in	O
an	O
ABI	O
PRISM	O
310	O
Genetic	O
Analyzer	O
(	O
Applied	O
Biosystems	O
,	O
Foster	O
City	O
,	O
CA	O
,	O
USA	O
).	O

Chromatin	O
immunoprecipitation	O
assay	O

Chromatin	O
immunoprecipitation	O
assays	O
were	O
performed	O
as	O
described	O
previously	O
[	O
36	O
].	O

Briefly	O
,	O
chromatin	O
isolated	O
from	O
cell	O
cultures	O
was	O
immunoprecipitated	O
using	O
the	O
following	O
antibodies	B-GP
:	O
anti	O
RNA	B-GP
pol	I-GP
II	I-GP
clone	O
CTD4H8	O
(#	O
05	O
-	O
623	O
,	O
Millipore	O
,	O
Bedford	O
,	O
MA	O
,	O
USA	O
),	O
H3K36me3	O
(#	O
ab9050	O
,	O
Abcam	O
,	O
Cambridge	O
,	O
UK	O
),	O
Sp1	B-GP
(	O
PEP	O
2	O
)	O
X	O
(#	O
SC	O
-	O
59X	O
,	O
Santa	O
Cruz	O
Biotechnology	O
,	O
Inc	O
.,	O
Santa	O
Cruz	O
,	O
CA	O
,	O
USA	O
)	O
and	O
normal	O
rabbit	B-OG
immunoglobulin	B-GP
(#	O
X0903	O
,	O
DakoCytomation	O
,	O
Denmark	O
).	O

The	O
recovered	O
DNA	O
was	O
analyzed	O
by	O
quantitative	O
real	O
-	O
time	O
PCR	O
with	O
SYBR	O
green	O
Master	O
Mix	O
in	O
an	O
ABI	O
7300	O
sequence	O
detection	O
system	O
(	O
Applied	O
Biosystems	O
).	O

The	O
qPCRs	O
were	O
performed	O
using	O
primers	O
designed	O
to	O
cover	O
three	O
different	O
regions	O
of	O
the	O
PDHA2	B-GP
gene	O
:	O
the	O
proximal	O
promoter	O
region	O
(+	O
1	O
bp	O
)	O
5	O
′-	O
GGCAGGCACTGTACAAATCA	O
-	O
3	O
′	O
(	O
forward	O
)	O
and	O
5	O
′-	O
CAGTGCACACGGGTGATAGA	O
-	O
3	O
′	O
(	O
reverse	O
);	O
the	O
CpG	O
island	O
II	O
region	O
(+	O
385	O
bp	O
)	O
5	O
′-	O
GGGCTCATGGTGTGTGCTAT	O
-	O
3	O
′	O
(	O
forward	O
)	O
and	O
5	O
′-	O
AGCACAACCTCCTCTTCTTCC	O
-	O
3	O
′(	O
reverse	O
);	O
and	O
a	O
distal	O
upstream	O
region	O
(−	O
10	O
Kb	O
)	O
5	O
′-	O
GCATGGCAGGACTTCTCTC	O
-	O
3	O
′	O
(	O
forward	O
)	O
and	O
5	O
′-	O
TTACAGGCAATGCTTG	O
ACCA	O
-	O
3	O
′	O
(	O
reverse	O
).	O

Statistical	O
analysis	O

Statistical	O
analysis	O
was	O
performed	O
using	O
the	O
Student	O
'	O
s	O
t	O
-	O
test	O
and	O
the	O
ANOVA	O
one	O
-	O
way	O
test	O
with	O
the	O
Tukey	O
Honestly	O
Significant	O
Differences	O
(	O
HSD	O
)	O
post	O
-	O
hoc	O
test	O
,	O
the	O
Tukey	O
HSD	O
for	O
unequal	O
N	O
(	O
Spjotvoll	O
/	O
Stoline	O
test	O
).	O

All	O
analyses	O
were	O
performed	O
using	O
the	O
STATISTICA	O
(	O
data	O
analysis	O
software	O
system	O
),	O
version	O
7	O
.	O
1	O
StatSoft	O
,	O
Inc	O
.	O

(	O
Tulsa	O
,	O
OK	O
,	O
USA	O
;	O
2006	O
).	O

A	O
value	O
of	O
p	O
<	O
0	O
.	O
05	O
was	O
considered	O
significant	O
.	O

Supporting	O
Information	O

Statistical	O
analysis	O
of	O
PDHA2	B-GP
gene	O
methylation	O
results	O
by	O
the	O
ANOVA	O
one	O
-	O
way	O
test	O
.	O

(	O
DOCX	O
)	O

Click	O
here	O
for	O
additional	O
data	O
file	O
.	O

Competing	O
Interests	O
:	O
The	O
authors	O
have	O
declared	O
that	O
no	O
competing	O
interests	O
exist	O
.	O

